Physician profile
Christopher Granger
NPI 1861472110
$13,457.32
in general payments reported to CMS, 2019-2025
20 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.81 · 2020: $13.53 · 2022: $1,765 · 2023: $168 · 2024: $11K · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,022 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,415 · Food and Beverage: $1,154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,022.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,415.00 |
| Food and Beverage | $1,154.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Roche Diagnostics International LTD | $10,841.41 | 2024 | |
| Medtronic, INC. | $1,731.43 | 2022 | |
| Irhythm Technologies, INC. | $227.39 | 2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $212.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $54.86 | 2019-2024 | Lokelma, Airsupra |
| Abbvie INC. | $52.28 | 2023-2024 | |
| Lilly USA, LLC | $43.17 | 2019-2025 | Zepbound, Mounjaro |
| Allergan, INC. | $41.28 | 2019 | |
| Amgen INC. | $33.93 | 2023-2024 | Repatha, Otezla |
| Abbott Laboratories | $30.28 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.41 | 2023-2024 | Jardiance |
| Philips North America LLC | $23.07 | 2023 | |
| Lundbeck LLC | $21.11 | 2025 | Rexulti |
| Mylan Specialty L.P. | $19.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.18 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.49 | 2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $17.23 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $14.88 | 2024 | Austedo Xr |
| Exact Sciences Corporation | $14.64 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $14.02 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Granger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.